ValiRx Plc’s or ‘The Company’ house broker, Hybridan LLP, will from time to time publish research notes from this page. Any opinions, estimates or forecasts regarding The Company’s performance made by the brokers are theirs alone and do not represent opinions, forecasts or predictions of The Company or its Management. By distributing the information below The Company does not imply its endorsement of or concurrence with such information.
Please click here to view ValiRx Plc’s Corporate Presentation.
ValiRx Plc – Latest News and Video Release – 18 May 2011:-
Satu Vainikka, from Valirx, talks about the unlimited potential of
“Dr Satu Vainikka, CEO at Valirx (LON:VAL), tells Proactive Investors
that there is tremendous potential for its GeneICE programme Satu
believes that the recently raised £3.3mln will see Valirx through to
pre-clinical studies at which point it is likely that a commercial joint
venture partner will be found within the sector.”
You will also find this published on:
Google Finance: http://www.google.com/finance?q=LON:VAL
One News Page: http://www.onenewspage.com/topic/ValiRx.htm
Moreover Technologies: http://w.moreover.com/public/free-rss/rss-feeds.html?query=%22ValiRx%22
You will also shortly find this news disseminated across our social
networking sites here:
Seeking Alpha: http://seekingalpha.com/author/proactive-investor/instablog
Word Press: http://proactiveinvestors.wordpress.com/
ValiRx held its last Annual General Meeting on 28 July 2008 in London. The notice together with the Chairman’s letter have been sent to shareholders and are also available for download by clicking below.
ValiRx held its first Annual General Meeting on 27th July 2007 in London. The notice of AGM together with the financial accounts for 2006 have been sent to shareholders and are also available for download by clicking on the links in PDF version:-